You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Fetal striatal transplantation in Huntington's disease: time for a pause
  1. R L Albin
  1. Department of Neurology, University of Michigan, and Geriatrics Research, Education, and Clinical Center, Ann Arbor VAMC, room 4412D, Kresge III Building, 200 Zina Pitcher Place, Ann Arbor, MI 48109-0585, USA
  1. Correspondence to:
 Dr R Albin;
 ralbin{at}umich.edu

https://doi.org/10.1136/jnnp.73.6.612

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The need to look at the rationale for fetal striatal transplantation

    In this issue of the Journal (pp 678–685),1 the NEST-UK consortium reports safety data on four subjects with Huntington's disease receiving unilateral intrastriatal transplantation of human fetal striatal tissue. This well designed and carefully executed study adds to the small amount of previous data on fetal striatal grafting for Huntington's disease.2,3,4 Groups in California and France reported a total of eight subjects receiving bilateral engraftment without complications and either no change in clinical outcome measures or some improvement.2,3 In another series of seven …

    View Full Text

    Linked Articles